Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;194(1):171-178.
doi: 10.1007/s10549-022-06611-6. Epub 2022 May 11.

Patient perspectives on window of opportunity clinical trials in early-stage breast cancer

Affiliations

Patient perspectives on window of opportunity clinical trials in early-stage breast cancer

Divya A Parikh et al. Breast Cancer Res Treat. 2022 Jul.

Abstract

Purpose: Window of opportunity trials (WOT) are increasingly common in oncology research. In WOT participants receive a drug between diagnosis and anti-cancer treatment, usually for the purpose of investigating that drugs effect on cancer biology. This qualitative study aimed to understand patient perspectives on WOT.

Methods: We recruited adults diagnosed with early-stage breast cancer awaiting definitive therapy at a single-academic medical center to participate in semi-structured interviews. Thematic and content analyses were performed to identify attitudes and factors that would influence decisions about WOT participation.

Results: We interviewed 25 women diagnosed with early-stage breast cancer. The most common positive attitudes toward trial participation were a desire to contribute to research and a hope for personal benefit, while the most common concerns were the potential for side effects and how they might impact fitness for planned treatment. Participants indicated family would be an important normative factor in decision-making and, during the COVID-19 pandemic, deemed the absence of family members during clinic visits a barrier to enrollment. Factors that could hinder participation included delay in standard treatment and the requirement for additional visits or procedures. Ultimately, most interviewees stated they would participate in a WOT if offered (N = 17/25).

Conclusion: In this qualitative study, interviewees weighed altruism and hypothetical personal benefit against the possibility of side effect from a WOT. In-person family presence during trial discussion, challenging during COVID-19, was important for many. Our results may inform trial design and communication approaches in future window of opportunity efforts.

Keywords: Breast cancer; Clinical trials; Patient perspectives; Window of opportunity.

PubMed Disclaimer

Conflict of interest statement

DAP, LK, SB, DH, VL, MK, IW, and GWS have no conflicts of interest to disclose. CC is a scientific advisor and consultant for Genentech, Grail, NanoString, DeepCell, Ravel, and ResistanceBio and has stock at Grail, Ravel, and DeepCell. MP is a consultant for Celgene and an advisor for Pacific Business Group. JLC has received research funding from QED Therapeutics and eFFECTOR Therapeutics to her institution.

Figures

Fig. 1
Fig. 1
Window of opportunity depiction
Fig. 2
Fig. 2
Theory of planned behavior

Similar articles

Cited by

References

    1. Caswell-Jin JL, Lorenz C, Curtis C. Molecular heterogeneity and evolution in breast cancer. Ann Rev Cancer Biol. 2021;5(1):79–94. doi: 10.1146/annurev-cancerbio-060220-014137. - DOI
    1. Vaz-Luis I, Zeghibe CA, Frank ES, et al. Prospective clinical experience with research biopsies in breast cancer patients. Breast Cancer Res Treat. 2013 doi: 10.1007/s10549-013-2717-5. - DOI - PMC - PubMed
    1. Kimmelman J, Resnik DB, Peppercorn J, Ratain MJ. Burdensome research procedures in trials: why less is more. J Natl Cancer Inst. 2017 doi: 10.1093/jnci/djw315. - DOI - PMC - PubMed
    1. Glimelius B, Lahn M. Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology. Ann Oncol. 2011 doi: 10.1093/annonc/mdq622. - DOI - PubMed
    1. Robertson JFR, Coleman RE, Cheung KL, et al. Proliferation and AKT activity biomarker analyses after capivasertib (AZD5363) treatment of patients with ER+ invasive breast cancer (STAKT) Clin Cancer Res. 2020;26(7):1574–1585. doi: 10.1158/1078-0432.CCR-19-3053. - DOI - PubMed